#1-88E. Beyond Weight Loss: GLP-1 Agonists and RA Disease Activity (ACR Open Rheumatology, 2025)

In this episode, we explore the potential dual benefits of GLP-1 receptor agonists (GLP-1RAs) in patients with rheumatoid arthritis (RA) and obesity. This retrospective study investigated the effects of GLP-1RAs, such as semaglutide and tirzepatide, on RA disease activity and cardiovascular risk profiles in overweight or obese patients. The findings revealed that patients treated with GLP-1RAs experienced significant reductions in RA disease activity, pain, body weight, total cholesterol, and HbA1c compared to a control group.The core finding is that GLP-1RA use was associated with improvements in both RA disease activity and cardiovascular risk factors. This suggests these medications may offer a dual-purpose treatment for RA patients with obesity, addressing both the inflammatory disease process and associated comorbidities. However, it is crucial to consider the study's limitations, including its single-center, retrospective design and the potential for unmeasured confounding factors. For clinicians, this research provides timely insights into integrating GLP-1RAs into treatment plans for RA patients with obesity, potentially improving quality of life and mitigating cardiovascular risk.Citation: KELLNER, David A., et al. Effect of Glucagon-Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis. ACR Open Rheumatology. 2025, 7(9), e70103. DOI: 10.1002/acr2.70103Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.